BioWorld - Tuesday, July 28, 2026 See today's BioWorld Home Pfizer M&A prospect Metsera heads to phase III with lead GLP-1 Phase IIb data of Metsera Inc.s lead GLP-1 receptor agonist, MET-097i, showed significant weight loss and good tolerability, supporting a phase III start later this year, and validating Pfizer Inc.s decision a week ago to buy the obesity-focused company for $7.3 billion
Is the solution clear and colorless
Female hair loss (androgenetic alopecia in women) involves the same follicle miniaturization mechanisms that GHK-Cu addresses follicle cell stimulation, anagen extension, and anti-inflammatory action
A licensed professional reviews your information to determine if a GLP-1 or dual agonist medication is safe and appropriate for you
Hallmark features of AD pathology include (I) age-dependent neurodegeneration that often manifests as gross neuroanatomical changes 12 - 14 , (II) the accumulation of pathological protein aggregates such as A plaques and neurofibrillary tangles (NFTs) 12 , (III) proliferation of glia (gliosis) and alterations in glial function that disrupt neuroimmune function and the blood brain barrier 12 , 15 , and (IV) an altered cellular landscape featuring multifaceted changes in cell signaling and metabolism, excessive oxidative stress, dysfunctional autophagy, impaired cell transport, and synaptic dysfunction 16 - 19
DAC is basically an ester like cypionate
